Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
Net income: US$65.2m (down 66% from 2Q 2023). Profit margin: 33%. EPS: US$0.25 (down from US$0.83 in 2Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Alvotech Earnings Insights Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 19% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for Alvotech (of which 1 doesn't sit too well with us!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not in
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® [Yahoo! Finance]Yahoo! Finance
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®GlobeNewswire
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswire
- Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week [Yahoo! Finance]Yahoo! Finance
- Alvotech (ALVO) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 8/30/24 - Form EFFECT
- 8/29/24 - Form 424B3
- 8/21/24 - Form F-3
- ALVO's page on the SEC website